Drugs / EVOLVE104
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07217171 | Nov 2025 → Jan 2029 expected | anal squamous cell carcinoma, cervical squamous cell carcinoma, esophageal squamous cell carcinoma, skin squamous cell carcinoma +7 | EvolveImmune United, Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-08-15 | EvolveImmune United, Inc | Regulatory EvolveImmune Therapeutics Announces FDA Clearance of Investigational New Drug Application for EVOLVE104, a Novel Trispecific T Cell Engager with Integrated CD2 Costimulation evolveimmune.com ↗
EvolveImmune Therapeutics, an immuno-oncology company developing next-generation T cell engager biotherapeutics to overcome cancer cell resistance to current immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for EVOLVE104, a novel trispecific T cell engager with integrated CD2 costimulation which targets the tumor-associated antigens ULBP2/5/6. |
| 2024-11-11 | EvolveImmune United, Inc | Results EvolveImmune Therapeutics Presents New Preclinical and Translational Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) evolveimmune.com ↗
Two poster presentations reported the latest preclinical results for the company’s lead development candidate, EVOLVE104, which is being developed for the treatment of solid tumors. |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVOLVE104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07217171 ↗ |
| Route | Intravenous | “EVOLVE104 is provided as a solution for injection via IV infusion” NCT07217171 ↗ |